Sweden
· Delayed Price · Currency is SEK Diagonal Bio AB Statistics
Total Valuation
Diagonal Bio AB has a market cap or net worth of SEK 18.22 million. The enterprise value is 17.41 million.
| Market Cap | 18.22M |
| Enterprise Value | 17.41M |
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Diagonal Bio AB has 1.21 billion shares outstanding. The number of shares has increased by 668.77% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.21B |
| Shares Change (YoY) | +668.77% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 11.69% |
| Owned by Institutions (%) | 3.57% |
| Float | 1.04B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.20 |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.75 |
| EV / Sales | 15.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03
| Current Ratio | 1.03 |
| Quick Ratio | 0.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.13 |
Financial Efficiency
Return on equity (ROE) is -43.32% and return on invested capital (ROIC) is -25.69%.
| Return on Equity (ROE) | -43.32% |
| Return on Assets (ROA) | -21.16% |
| Return on Invested Capital (ROIC) | -25.69% |
| Return on Capital Employed (ROCE) | -38.30% |
| Revenue Per Employee | 225,000 |
| Profits Per Employee | -1.99M |
| Employee Count | 5 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.23 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.96% in the last 52 weeks. The beta is -1.82, so Diagonal Bio AB's price volatility has been lower than the market average.
| Beta (5Y) | -1.82 |
| 52-Week Price Change | -85.96% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 53.55 |
| Average Volume (20 Days) | 6,514,747 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diagonal Bio AB had revenue of SEK 1.13 million and -9.93 million in losses. Loss per share was -0.04.
| Revenue | 1.13M |
| Gross Profit | 942,000 |
| Operating Income | -9.42M |
| Pretax Income | -9.93M |
| Net Income | -9.93M |
| EBITDA | -8.41M |
| EBIT | -9.42M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 818,000 in cash and n/a in debt, giving a net cash position of 818,000 or 0.00 per share.
| Cash & Cash Equivalents | 818,000 |
| Total Debt | n/a |
| Net Cash | 818,000 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 24.60M |
| Book Value Per Share | 0.06 |
| Working Capital | 65,000 |
Cash Flow
| Operating Cash Flow | -13.77M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 83.73% |
| Operating Margin | -837.42% |
| Pretax Margin | -882.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Diagonal Bio AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -668.77% |
| Shareholder Yield | -668.77% |
| Earnings Yield | -54.49% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Diagonal Bio AB has an Altman Z-Score of -0.37. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.37 |
| Piotroski F-Score | n/a |